Trial Profile

A Phase 1b allogeneic gamma-delta T cell study in patients with relapsed Glioblastoma Multiforme

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 15 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INB-400 (Primary)
Indications Glioblastoma
Focus Therapeutic Use

Most Recent Events

10 May 2024 According to an IN8bio media release, the company expects to treat up to a total of 40 patients in arm A at multiple sites across the United States.
10 May 2024 According to an IN8bio media release, the company announced first patient dosed in the Phase 2 autologous arm of INB-400 in patients with newly diagnosed GBM.
10 May 2024 According to an IN8bio media release,Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com